Patent ID: 9261512
Filing Date: 2016-02-16
CPC Classification: A61K,A61P,C12N,G01N

Claim Text:
1. A method of treating a cancer patient, the method comprising administering an effective amount of an immunogenic composition comprising a vaccinia virus vector comprising a heterologous nucleotide sequence encoding MUC-1 to a cancer patient identified as having an interleukin 10 (IL-10)/interferon γ (IFNγ) ratio below 5 prior to administration of the immunogenic composition, wherein the IL-10/IFNγ ratio is calculated by measuring the levels of IL-10 and IFNγ in a biological sample from the patient prior to administration of the immunogenic composition and determining the IL-10/IFNγ ratio based on the measured levels of IL-10 and IFNγ.